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Human group IIA-secreted phospholipase A2 (sPLA2-IIA) is
an important regulator of cytokine-mediated inflammatory
responses in both in vitro and in vivomodels of rheumatoid
arthritis (RA). However, treatment of RA patients with sPLA2-
IIA inhibitors shows only transient benefit. Using an activity-
impaired sPLA2-IIA mutant protein (H48Q), we show that
up-regulation of TNF-dependent PGE2 production and cy-
clooxygenase-2 (COX-2) induction by exogenous sPLA2-IIA in
RA fibroblast-like synoviocytes (FLSs) is independent of its
enzyme function. Selective cytosolic phospholipase A2-
(cPLA2-) inhibitors abrogate TNF/sPLA2-IIA-mediated PGE2
production without affecting COX-2 levels, indicating arachi-
donic acid (AA) flux to COX-2 occurs exclusively through
TNF-mediated activation of cPLA2-. Nonetheless, exogenous
sPLA2-IIA, but not H48Q, stimulates both AAmobilization
from FLSs and microparticle-derived AA release that is not
used for COX-2-dependent PGE2 production. sPLA2-IIA-me-
diated AA production is inhibited by pharmacological block-
ade of sPLA2-IIA but not cPLA2-. Exogenous H48Q alone,
like sPLA2-IIA, increases COX-2 protein levels without induc-
ing PGE2 production. Unlike TNF, sPLA2-IIA alone does not
rapidly mobilize NF-B or activate phosphorylation of p38
MAPK, two key regulators of COX-2 protein expression, but
does activate the ERK1/2 pathway. Thus, sPLA2-IIA regulates
AA flux through the cPLA2-/COX-2 pathway in RA FLSs by
up-regulating steady state levels of these biosynthetic enzymes
through an indirect mechanism, rather than direct provision
of substrate to the pathway. Inhibitors that have been opti-
mized for their potency in enzyme activity inhibition alone
may not adequately block the activity-independent function of
sPLA2-IIA.
Phospholipase A2 (PLA2)2 enzymes regulate the provision
of arachidonic acid (AA) to the cyclooxygenase (COX) and
lipoxygenase biosynthetic pathways, the products of which, in
turn, are critical autocrine and paracrine regulators of diverse
physiological processes in mammals. Of the 23 currently
known mammalian PLA2 enzymes, in vivo gene deletion stud-
ies in mice have established the widely expressed intracellular
enzyme cytosolic PLA2- (cPLA2-, Group IVA PLA2) as an
important enzyme in providing AA substrate to COX and
lipoxygenase because deletion of this gene product abrogates
eicosanoid production in cells stimulated ex vivo (1, 2). Signif-
icantly, cPLA2- gene deletion markedly reduces disease se-
verity in the collagen-induced arthritis model of rheumatoid
arthritis (RA), suggesting cPLA2- has a key role in the patho-
genesis of RA (2).
The contribution of the remaining 18 PLA2 enzymes to AA
metabolism and to immune-mediated, inflammatory pathol-
ogy is less clear. Macrophages from Group V secreted PLA2
(sPLA2)-deficient mice show impaired production of both
COX- and lipoxygenase-derived eicosanoid products in re-
sponse to the inflammatory stimulus zymosan (3), whereas
deletion of Group X sPLA2 results in impaired eicosanoid
release into the lungs following ovalbumin challenge (4).
sPLA2-IIA, the best studied of the 10 mammalian sPLA2
enzymes, is not expressed in certain mouse strains with re-
stricted expression in others compared with either rats or
humans (5, 6), making classical genetic deletion experiments
impractical for this enzyme. Despite this, a proinflammatory
role for sPLA2-IIA in arthritis has been confirmed by recent
genetic studies showing that arthritis is attenuated in sPLA2-
IIA knock-out mice, relative to congenic wild-type mice, in a
K/BxN serum transfer model of arthritis (7). Surprisingly,
these studies also showed that Group V sPLA2 has an anti-
inflammatory role in this model of arthritis (7). Transgenic
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expression of human sPLA2-IIA in mice results in spontane-
ous atherosclerosis (8) that is transferable to non-transgenic
mice by transplantation of transgenic bone marrow (9). Thus,
aberrant expression of the human enzyme, in vivo, induces
inflammatory pathology. These animals do not develop spon-
taneous arthritis (10), however, transgenic expression of hu-
man sPLA2-IIA leads to earlier onset and more severe arthri-
tis in a TNF transgenic, spontaneous arthritis model (11)
implicating aberrant expression of sPLA2-IIA as a positive
regulator of cytokine-mediated joint inflammation. Further-
more, transgenic expression of human sPLA2-IIA in mice re-
sults in increased severity in the K/BxN serum transfer arthri-
tis model (7).
sPLA2-IIA is markedly induced in the serum of patients
with immune-mediated conditions, including RA and in tis-
sues of patients with certain cancers (12–14). Serum enzyme
activity and concentration correlate with disease severity in
RA (15), synovial tissue expression of sPLA2-IIA correlates
with histological markers of inflammation (16), and several
other sPLA2 enzymes are also expressed in RA synovial tissue
(17) and synovial fluid (7). Exogenous addition of sPLA2-IIA
to cultured RA synovial cells, at concentrations found in the
synovial fluids of RA patients, enhances both TNF-stimulated
PGE2 production and up-regulation of the inducible cyclooxy-
genase, COX-2 by an unknown mechanism (18). However,
blockade of enzyme activity with a potent inhibitor of sPLA2-
IIA, Group V and Group X sPLA2 (in a randomized, double-
blinded, placebo-controlled study) shows only transient bene-
fit in patients with active RA (19)). Thus, despite compelling
preclinical and early phase clinical data (19), the utility of
sPLA2-IIA blockade in the treatment of arthritis is not well
supported by the most recent clinical evidence.
Here we show for the first time in cells that mediate inflam-
matory synovitis in RA that although exogenous sPLA2-IIA
contributes to AA flux in these cells in culture, exogenous
sPLA2-IIA-amplified cytokine-mediated PGE2 production is
sPLA2-IIA enzyme activity-independent and is thus mediated
by a signaling function of the enzyme that indirectly up-regu-
lates levels of the cPLA2-/COX-2 pathway enzymes.
EXPERIMENTAL PROCEDURES
Materials—sPLA2-IIA protein was expressed, purified, and
quantified as described (18). cPLA2- inhibitors pyrrolidine-1
(20, 21) and pyrrophenone (22, 23) were synthesized as de-
scribed. Pyrrolidine-1 inhibited purified, recombinant
cPLA2- in a vesicle assay with an IC50 of 70 nM, and AA re-
lease in ionomycin-stimulated Madin-Darby canine kidney
cells with an IC50 of 800 nM. It showed no detectable inhibi-
tion of purified, recombinant human sPLA2-IIA, Group V or
Group X sPLA2 at 10 M concentration, and no physiologi-
cally relevant inhibition of recombinant cytosolic PLA2- or
the calcium-independent PLA2, iPLA2 (20). Pyrrophenone
inhibited recombinant cPLA2- in a mixed-micelle assay with
an IC50 of 80 nM (24) without significant inhibition of all five
remaining human cPLA2 isoforms in this assay.3 It inhibited
AA release and PGE2 production in ionophore-stimulated
THP-1 cells with an IC50 of 25 nM (25) and had no apprecia-
ble inhibition of murine cytosolic PLA2- (24) or purified,
recombinant human Group IB sPLA2 or sPLA2-IIA at 200 M
(25). The sPLA2 inhibitor c(2NapA)LS(2NapA)R was synthe-
sized as previously described (Auspep, Melbourne, Australia)
(26). LY311727 was a kind gift from Eli Lilly and Co. (Indian-
apolis, IN). The iPLA2- inhibitor, bromoenol lactone, was
obtained from Sigma.
Construction of sPLA2-IIA Catalytic Site Mutant H48Q—
The sPLA2-IIA cDNA (a kind gift from J. Seilhamer) (27) was
subcloned into pBlueScribe() and histidine 48 was substi-
tuted for glutamine by oligonucleotide-directed mutagenesis
of the His codon (non-coding strand oligonucleotide
sequence 5-AGCAACAGTCCTGAGTGACAC-3). Mu-
tagenesis was carried out with an in vitro mutagenesis kit
(Amersham Biosciences) based on the method of Eckstein
and co-workers (28). The nucleotide sequence of the mu-
tagenized construct was confirmed and the cDNA was cloned
into the zinc-inducible mammalian expression vector
pMTSV40polyABam (pLEN) (29). The resultant plasmid
(pMIK-1) was co-transfected with pRSV2-neo, carrying a
G418 resistance gene, into Chinese hamster ovary (CHO)
cells by calcium phosphate precipitation. Following several
rounds of G418 selection, the resultant cell culture pool was
used to express H48Q, and the protein was purified from con-
ditioned medium by affinity chromatography (AKTA Ex-
plorer purification system, GE Healthcare) as described for
sPLA2-IIA (18), and quantified by ELISA (12).
sPLA2 Enzyme Activity Assay—sPLA2 enzyme activity was
measured with a colorimetric microtiter plate, mixed micelle
assay (Cayman Chemical, Ann Arbor, MI) using diheptanoyl-
thiophosphatidylcholine as substrate (30) with the following
modifications. Briefly, enzyme (10 l, 2.5 g/ml, sPLA2-IIA or
H48Q) diluted in assay buffer (10 mM CaCl2, 100 mM KCl, 0.3
mM Triton X-100, 1 mg/ml of BSA, 25 mM Tris-HCl, pH 7.5)
was added to each well containing the free-thiol detection
reagent 5,5-dithio-bis-(2-nitrobenzoic acid) (10 l, 10 mM
5,5-dithio-bis-(2-nitrobenzoic acid) in 0.4 M Tris-HCl, pH
8.0) and 5 l of assay buffer. Phospholipid substrate was re-
constituted in assay buffer to a final concentration of 1.66 mM
with vortexing until the solution was clear, then preheated to
40 °C. Assays were performed at 40 °C, started by addition of
substrate (200 l/well) and A405 was measured every 3 min
over a 60-min time course (Spectramax 250 microtiter plate
reader, Molecular Devices, Sunnyvale CA). Assays were per-
formed in triplicate relative to blank wells containing assay
buffer and data were analyzed using SoftMax Pro version 1.1
software in kinetic mode.
Fibroblast-like Synoviocytes—Synovial tissue was obtained
from patients undergoing joint surgery and who were diag-
nosed with RA according to American Rheumatism Associa-
tion criteria (31) using procedures approved by the St. Vin-
cent’s Hospital Ethics Committee. Fibroblast-like synoviocyte
(FLS) cultures were established as described (18) and used
between passages 3 and 10. Cells, CD14-negative and
4-prolylhydroxylase-positive by immunohistochemistry and
CD21-negative by RT-PCR, were grown in Ham’s/DMEM
containing 10% FBS and used at 80–90% confluence.3 M. H. Gelb, unpublished data.
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PGE2 Assay—Cells, grown in 96-well plates were stimu-
lated, medium was harvested and stored at80 °C prior to
PGE2 assay. Cells were lysed in wells by resuspension in ice-
cold lysis buffer (40 l) containing 1% (v/v) Nonidet P-40,
0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS, 1 mM
EGTA, 50 g/ml of aprotinin, 200 M leupeptin, 1 mM PMSF
in PBS. Lysates from triplicate experiments were combined
and stored at80 °C prior to protein determination (Bio-Rad
DC Protein Assay, Bio-Rad). PGE2 in medium was deter-
mined by enzyme immunoassay (Cayman Chemical) as previ-
ously described (18) and expressed as picograms of PGE2/mg
of total cellular protein.
Nuclear Protein Extracts—FLSs, grown in 150-cm2 flasks,
were stimulated and nuclear extracts were prepared as de-
scribed (32) with minor modification as follows. Cells were
harvested with trypsin/EDTA, centrifuged (4000 g, 1 min),
supernatants were discarded, cell pellets were washed with
PBS (1 ml), recentrifuged, and placed on ice. Cells were resus-
pended in ice-cold Buffer A (175 l, 10 mM KCl, 1.5 mM
MgCl2, 100 mM EDTA, 1 mM DTT, 1 M PMSF, 100 g/ml of
aprotinin, 100 mg/ml of leupeptin, 10 mM HEPES, pH 7.9)
and incubated on ice for 5 min. Nonidet P-40 (9 l, 10% v/v)
was added, samples were vortexed for 10 s, centrifuged (20 s,
13,790 g), and supernatants were discarded. Pellets were
washed gently with ice-cold buffer A (150 l), centrifuged,
and supernatants were discarded. Buffer C (40 l, 420 mM
KCl, 1.5 mM MgCl2, 100 mM EDTA, 1 mM DTT, 1 mM PMSF,
100 g/ml of aprotinin, 100 g/ml of leupeptin, 10 mM
HEPES, pH 7.9) was added, samples were vortexed (10 s) and
incubated with orbital shaking for 30 min on ice. Samples
were centrifuged (13,790 g, 15 min, 4 °C), supernatants
were divided into aliquots and stored at80 °C prior to use.
Protein concentration was determined by the Bradford pro-
tein assay (Bio-Rad).
Western Blot Analysis—Cells were grown in 24-well plates,
stimulated, and medium was harvested and stored at80 °C.
Cells were lysed, triplicate wells were combined and protein
determinations made as described above. For phosphoprotein
determination experiments, cells were grown in 75-cm2
flasks, treated, and washed once with ice-cold PBS (10 ml/
flask) containing 10 mM orthovanadate. Cells were scraped
into ice-cold PBS (1 ml) containing 5.3 mM EDTA, 10 mM
sodium orthovanadate, 50 mM disodium -glycerophosphate,
and 10 mM NaF. Following centrifugation the cells were lysed
in 1% (v/v) Nonidet P-40, 0.5% (w/v) sodium deoxycholate,
0.1% (w/v) SDS, 1 mM EGTA, 50 g/ml of aprotinin, 200 M
leupeptin, 1 mM PMSF, 10 mM sodium orthovanadate, 50 mM
disodium -glycerophosphate, and 10 mM NaF in PBS. Pro-
tein (15–20 g/well) was electrophoresed on polyacrylamide
gels (4–20% BisTris (2-[bis(2-hydroxyethyl)amino]-2-(hy-
droxymethyl)propane-1,3-diol) gels, Novex) according to the
manufacturer’s instructions and transferred to nitrocellulose
as described (18). Primary Abs for cPLA2-, COX-1, COX-2,
and -actin and secondary Abs were used as described previ-
ously (18). Murine monoclonal anti-human c-Jun Ab (Santa
Cruz Biotechnology, Santa Cruz, CA; number sc-822) was
used at 0.2 g/ml and detected with sheep anti-mouse IgG-
horseradish peroxidase (HRP) (GE Healthcare, 1/3000). Rab-
bit polyclonal Abs were used at the following concentrations:
anti-human IB- (Santa Cruz, number sc-371), 10 ng/ml;
anti-mouse IB- (Santa Cruz, number sc-945), 400 ng/ml;
anti-human NF-B p50 (Santa Cruz, number sc-114), 4 g/
ml; anti-human NF-B p65 (Santa Cruz, number sc-109), 1
g/ml; anti-human phospho-p38 MAP kinase Ab (phospho-
Thr180/phospho-Tyr182, New England Biolabs, number 9211),
1/1000 dilution; anti-human p38MAP kinase (Santa Cruz,
number sc-535), 33 ng/ml, anti-human phospho-ERK (phos-
pho-Thr202/phosphoTyr204) (Cell Signaling Technologies,
number 9101), 1/10,000 dilution; and anti-rat ERK1 (Santa
Cruz, number sc-94, ERK-2 cross-reactive), 10 ng/ml. These
Abs were detected with donkey anti-rabbit IgG horseradish
peroxidase conjugate (GE Healthcare, 1/3000 dilution). Bands
were visualized using chemiluminescence (Renaissance
chemiluminescent reagent Plus, New England Nuclear) with
detection on x-ray film (Hyperfilm ECL, GE Healthcare).
Bands were scanned (PDI densitometer, Molecular Dynamics)
and density was quantified with IPLabgelH software (Macin-
tosh version 1.5g).
NF-B Gel Shift Assays—NF-B binding to a double-
stranded consensus NF-B binding site oligonucleotide with
top strand sequence (5-AGTTGAGGGGACTTTC-
CCAGGC-3), 5-end-labeled with [-32P]ATP (GE Health-
care), and T4 polynucleotide kinase (Promega) was measured
by electromobility shift assay (EMSA) as described (33).
Briefly, nuclear extracts (5 g of total protein), prepared as
described above, were added to a binding reaction (20 l)
containing (polydeoxyinosine (dI)-deoxycytidine (dC))
(polydI-dC) (GE Healthcare) at 0.25 g/g of total protein,
1–2 ng of 32P-labeled double-stranded oligonucleotide probe
and DNA binding buffer (20 mM HEPES, pH 7.9, 1 mM EDTA,
pH 8.0, 60 mM KCl, 1 mM DTT, glycerol (12% v/v)). The bind-
ing reaction was incubated at room temperature for 30 min
prior to electrophoresis on non-denaturing polyacrylamide
gels (5% polyacrylamide) in 0.25 Tris borate EDTA (TBE)
buffer, pH 8.3, at 150 V for 2–3 h. Gels were dried and bands
were imaged with x-ray film (X-Omat AR, Kodak, Sydney,
Australia). NF-B EMSA bands were confirmed by NF-B
cold-competitor studies and supershift of NF-B EMSA
bands, using anti-p65 and anti-p50 Abs, were performed on
nuclear extracts from TNF--stimulated FLSs.
AAMobilization Assays—Cells were grown in 96-well
plates and labeled with [5,6,8,9,11,12,14,15-3H]AA
(PerkinElmer Life Sciences; NET-298Z) in Ham’s/DMEM
containing 10% FBS for 16 h at 37 °C. Cells were washed 3
times in PBS containing 0.1% (w/v) BSA (fatty acid free,
Sigma) and stimulated for the indicated times in Ham’s/
DMEM containing 0.1% (w/v) BSA. Treatments were added
simultaneously with stimulants. Medium was harvested, cells
were detached with trypsin/EDTA, and tritium was deter-
mined in medium and cells by scintillation counting (LS6000
TA, Beckman, Sydney, Australia). Data are expressed as %
total radioactivity (cells plus medium) released into medium.
Thin Layer Chromatography—Samples (50 l), to which
unlabeled AA (1 g) had been added, were spotted onto silica
gel plates (Merck, Darmstadt, Germany), air dried, and eluted
in chloroform:methanol:acetic acid:water (90:8:1:0.8) (34).
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Plates were air-dried and developed in iodine vapor to identify
the AA spot. Eluted samples were cut into seven equal seg-
ments in order of increasing Rf value and tritium was deter-
mined by scintillation counting (LS6000 TA, Beckman, Syd-
ney, Australia). Data for each segment were expressed as %
total radioactivity recovered from each sample for each
segment.
Statistical Analysis—Data were analyzed and plotted using
Prism Graphpad version 4.0. Statistical significance was deter-
mined using the Student’s paired t test unless otherwise
stated.
RESULTS
Exogenous sPLA2-IIA Up-regulates TNF-mediated PGE2
Production and COX-2 Protein by an Activity-independent
Mechanism—To determine whether sPLA2-IIA enzyme activ-
ity was necessary for up-regulation of TNF-dependent PGE2
production and COX-2, we constructed an “activity-im-
paired” mutant of sPLA2-IIA (H48Q) by site-directed mu-
tagenesis as described under “Experimental Procedures.”
Quantification of H48Q was determined relative to a sPLA2-
IIA standard by ELISA (35). The ELISA was validated for
H48Q by quantitative amino acid analysis of 2 independent
samples of sPLA2-IIA and H48Q, followed by quantitation of
each sample in the same ELISA. Equivalent concentrations
were obtained for each sample by both methods (data not
shown). Importantly, the mol % amino acid composition for
each amino acid obtained for both sPLA2-IIA and H48Q in
the amino acid analysis was not significantly different from
the theoretical composition calculated from their known pro-
tein sequences (p 1.0000, p 0.9926 for sPLA2-IIA and
H48Q respectively, Student’s paired t test), confirming that
both proteins were99% pure. This mutation has been re-
ported by others to have 2–4% residual enzyme activity (36).
In our hands purified H48Q had 1% residual sPLA2-IIA activ-
ity, with a specific activity of 0.28 0.12 mol of dihep-
tanoylthiophosphatidylcholine/min/mg of protein (data are
mean S.D. of three experiments performed in triplicate)
relative to 27.8 2.3 mol of diheptanoylthiophosphatidyl-
choline/min/mg of protein for sPLA2-IIA. Our purified H48Q
protein lacks the proliferative capacity of purified sPLA2-IIA
in the LNCaP prostate cancer cell line (37), confirming that
the 1% residual enzyme activity we measure in our H48Q
preparations is insufficient to recapitulate the effects of fully
active sPLA2-IIA in these cells. In FLSs, H48Q alone like
sPLA2-IIA, had no effect on PGE2 production (Fig. 1A) at en-
zyme concentrations that are found in synovial fluid (18).
TNF alone resulted in a 15-fold stimulation of PGE2. H48Q
increased this stimulation to30-fold, as did sPLA2-IIA. In
both cases PGE2 production was completely abrogated by the
COX-2-selective inhibitor NS-398. In a side by side experi-
ment with sPLA2-IIA, H48Q-mediated PGE2 production was
dose-dependent with both mutant and native enzyme having
no effect at concentrations below 100 ng/ml (7 nM) (data not
shown). In agreement with our earlier work (18), TNF alone
up-regulated steady state COX-2 protein levels (Fig. 1B).
H48Q alone (Fig. 1B), as with sPLA2-IIA (18), also increased
COX-2 protein, despite having no effect on PGE2 production
(Fig. 1A). As we have also shown for sPLA2-IIA, H48Q, in
combination with TNF, synergistically up-regulated COX-2
protein (Fig. 1B) without any effect on COX-1 (data not
shown).
cPLA2-Mediates sPLA2-IIA-dependent PGE2 Production
but Not COX-2 Up-regulation—To determine whether PGE2
production in response to TNF and sPLA2-IIA was dependent
on cPLA2-, we used a pharmacological approach with well
FIGURE 1.Up-regulation of cytokine-dependent PG production and
COX-2 does not require sPLA2-IIA enzyme activity. A, FLS cells, grown to
80–90% confluence, were stimulated with TNF (10 ng/ml), alone or in com-
bination with the activity-impaired mutant of sPLA2-IIA (H48Q) (4 g/ml), or
with sPLA2-IIA (WT) (4 g/ml) in the presence or absence of the COX-2-se-
lective inhibitor NS-398 (1 M) for 16 h in DMEM/Ham’s F-12 containing
0.1% BSA. PGE2 concentration was measured in cell culture supernatants
and total cellular protein was determined as described under “Experimental
Procedures.” Data are combined mean S.E. of triplicate determinations
from cell cultures derived from each of 4 patients. *, p	 0.05; **, p	 0.01;
***, p	 0.001 (Student’s unpaired t test) relative to unstimulated cells un-
less indicated. B, cells were treated for 16 h as indicated, lysed, and protein
extracts were subjected to electrophoresis and Western blot analysis as de-
scribed under “Experimental Procedures.” A representative Western blot
from one cell culture (RA79) is shown. Bands were quantified by densitome-
try as described. COX-2 density for each sample was normalized relative to
-actin density and the COX-2/-actin ratio for each treatment was then
normalized relative to control for each cell culture. Data are mean S.E. of
three independent cell cultures.
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characterized pyrrolidine inhibitors that selectively block hu-
man cPLA2- activity over other human cPLA2 isoforms,
iPLA2- or sPLA2 activities (20–25). Pyrrophenone (5 M)
completely blocked the PGE2 response to TNF alone, sub-
stantially suppressed the response to TNF/sPLA2-IIA and
showed a small but significant inhibition of the sPLA2-IIA/
TNF response at 1 M (Fig. 2A). Pyrrolidine-1 abrogated
PGE2 production in response to sPLA2-IIA/TNF stimulation
at all concentrations tested (Fig. 2B), without any effect on
basal PGE2 production. However, pyrrophenone, at concen-
trations that abrogate PGE2 production, did not significantly
block sPLA2-IIA-mediated COX-2 up-regulation (Fig. 2C).
Thus provision of AA to COX-2 for both TNF-dependent and
sPLA2-IIA up-regulated PGE2 production appears to be medi-
ated by cPLA2-.
Effect of sPLA2-IIA on AA Mobilization—In light of these
data and reports that exogenous sPLA2-IIA does not effi-
ciently mobilize AA in attachment dependent cells in culture
(38), the effect of TNF and exogenous sPLA2-IIA on AA mo-
bilization was examined by [3H]AA release assays. First, the
assay was validated by examining the response of FLSs to the
known AA-mobilizing agonist bradykinin (BK) (Fig. 3A). BK
stimulation (10 nM, 15 min) resulted in increased [3H]AA re-
lease from 8.0 0.8% (mean S.E. of duplicate experiments
from 4 independent cell cultures) in untreated cells to 11.3
0.6% total counts incorporated (p	 0.05), consistent with a
previous report (39). Release peaked by 2 h post-stimulation
(21.0 1.2% total counts, p	 0.05 relative to unstimulated
cells). The basal level of AA release also increased rapidly with
time peaking at 2 h (12.9 1.8% total counts) with similar
kinetics to stimulated cells. Subsequent studies were termi-
nated 2 h post-stimulation. Under these conditions, pyrro-
phenone (5 M) blocked BK-dependent AA release (Fig. 3B).
We next examined the effect of sPLA2-IIA, alone or in
combination with TNF in the presence or absence of pyrro-
phenone on AA release. Pyrrophenone alone showed a small
but significant reduction in basal AA release (Fig. 3C). Ba-
sal AA release was unaffected by the calcium-independent
Group VIA PLA2 (iPLA2-) inhibitor, bromoenol lactone
(40) (10 M) (data not shown). TNF stimulation resulted in
a 1.2-fold increase in AA release that was abrogated by pyr-
rophenone. Surprisingly, at concentrations that fail to
stimulate PGE2 production, sPLA2-IIA alone increased AA
release by 1.5-fold and the increase was not inhibited by
pyrrophenone. sPLA2-IIA in combination with TNF re-
sulted in a 1.7-fold increase over untreated cells that was
not significantly affected by pyrrophenone. As with previ-
ous experiments, BK stimulated AA release by 1.3-fold and
this was inhibited by pyrrophenone.
The dose responsiveness of sPLA2-IIA-mediated AA re-
lease and the effect of selective sPLA2 inhibition on the re-
sponse were then determined (Fig. 4A). sPLA2-IIA dose de-
pendently induced AA release at concentrations above 1
g/ml (71 nM) but was ineffective at 100 ng/ml (7 nM) con-
centration. Co-incubation with the selective sPLA2 inhibitor
c(2NapA)LS(2NapA)R (26) (1 M) resulted in significant inhi-
bition of the response at a molar ratio of inhibitor to enzyme
approaching 1:1 and complete inhibition of the response at a
FIGURE 2. PGE2 production, but not COX-2 up-regulation is dependent
on cPLA2- enzyme activity. 80–90% confluent FLSs were stimulatedwith
TNF (10 ng/ml), sPLA2-IIA (4g/ml) either alone or in combination in the pres-
ence or absence of the cPLA2--selective inhibitor (A) pyrrophenone or (B) pyr-
rolidine-1 at the concentrations shown for 16 h in Ham’s/DMEMmedium con-
taining 0.1%BSA.Medium and cells were harvested, PGE2 inmediumwas
determined and the protein concentration in cell lysates determined as de-
scribed under “Experimental Procedures.” Data aremean S.E. of triplicate
determinations from cell cultures derived from each of four patients. **, p	
0.01; ***, p	 0.001 (Student’s unpaired t test) relative to unstimulated cells un-
less indicated. C, cells were grown in 24-well plates and stimulated as described
above. Cells were harvested, lysateswere electrophoresed, transferred to nitro-
cellulose, probedwith Abs, and labeled proteinswere visualized on x-ray film
by enhanced chemiluminescence, blots were scanned and densitometry per-
formed and analyzed as described under “Experimental Procedures.” Repre-
sentative blots fromone cell culture are shown. Densitometry data aremean
S.E. normalized relative to unstimulated cells from experiments performed on
cell cultures derived from three separate patients.
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molar ratio of 3.5:1. Because this inhibitor also suppresses the
activity-independent functions of exogenous sPLA2-IIA, viz.
sPLA2-IIA-mediated up-regulation of cytokine-dependent
PGE2 production (26), the effect of H48Q on AA release was
determined in a side by side experiment with sPLA2-IIA.
H48Q was ineffective at concentrations where sPLA2-IIA
stimulates AA mobilization (Fig. 4B), confirming that sPLA2-
IIA enzyme activity mediates the response.
FLSs are known to spontaneously release microparticles
into culture medium (41), and purified microparticles derived
from other cell types, particularly platelets, are known to am-
plify inflammation in arthritis models (42). It is possible that
the AA mobilization measured here could reflect micropar-
ticle release from FLSs in addition to free AA. To evaluate this
possibility, we examined the distribution of tritium in phos-
pholipid (PL), arachidonic acid, and other lipid mediator frac-
tions of conditioned medium derived from labeled cells fol-
lowing 2 h stimulation, by thin layer chromatography (TLC).
More than half (63%) of the tritium released into supernatants
of resting labeled cells remained associated with phospholip-
ids on TLC (Table 1), whereas 20% coeluted with AA. The
remaining 17% was evenly distributed between these frac-
tions. TNF stimulation showed no change in the distribution
of tritium in phospholipids and a trend to increased tritium in
AA. In the presence of sPLA2-IIA, the distribution of AA in
phospholipids was significantly reduced relative to unstimu-
lated cells with a trend to increased tritium distributed evenly
between AA and other lipid mediators. This distribution pat-
FIGURE 3. Effect of sPLA2-IIA on AAmobilization in RA FLSs. Human sy-
novial FLSs were labeled with [3H]AA and stimulated (A) with (closed circles)
or without (open circles) BK (10 nM) or (B, C) as indicated in the presence or
absence of pyrrophenone (Pyr) for 2 h prior to harvesting medium and cells
for AA release determination as described under “Experimental Proce-
dures.” Data are mean S.E. of two independent experiments combined,
each comprising duplicate determinations from four independent cultures.
*, p	 0.05; **, p	 0.05; ***, p	 0.001 (Student’s paired t test) relative to
control unless indicated. Total radioactivity incorporated into cells ranged
from 8,185–38,367 dpm.
FIGURE 4. sPLA2-IIA-dependent AAmobilization requires sPLA2-IIA en-
zyme activity. FLSs were labeled with [3H]AA, incubated for 2 h: A, in the
presence or absence of the sPLA2-IIA inhibitor c(2Nap)LS(2Nap)R (C2), at 1
M concentration (26) and in the presence or absence of sPLA2-IIA as indi-
cated; or B, in the presence or absence of sPLA2-IIA or the activity-impaired
mutant H48Q. AA release was measured as described under “Experimental
Procedures.” Data are mean S.E. of duplicate determinations from three
to four cell cultures derived from separate patients and are representative
of two independent experiments. **, p	 0.01; ***, p	 0.001 (Student’s un-
paired t test) relative to unstimulated cells unless indicated. Total radioac-
tivity incorporated into cells ranged from: A, 18,733–40,749 dpm; B, 12,523–
35,086 dpm.
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tern was largely recapitulated in cells stimulated with TNF
sPLA2-IIA (Table 1).
Effect of sPLA2-IIA on NF-B Mobilization, p38 MAPK, and
ERK MAPK Activation—Enhanced TNF-dependent PGE2
production in the presence of sPLA2-IIA appears to result
from induction of COX-2 rather than sPLA2-IIA-mediated
increased AA flux through the COX-2 pathway. COX-2 pro-
tein induction in FLSs is regulated in response to certain ago-
nists at the level of transcription via NF-B activation (43),
ERK MAPK activation (44), and/or post-transcriptionally
through regulation of mRNA stability that requires phosphor-
ylation of the MAPK p38 (45). To determine whether sPLA2-
IIA was activating these pathways in FLSs, the effect of exoge-
nous enzyme on rapid activation of the NF-B pathway, p38,
and ERK phosphorylation was determined. An EMSA was
established to measure direct binding of nuclear proteins to a
consensus NF-B DNA binding sequence. Supershift assays
with anti-p65 and anti-p50 Abs (Fig. 5A) and competition
experiments with cold binding sequence (data not shown)
demonstrated the specificity of this assay for NF-B subunits.
Unlike TNF, sPLA2-IIA alone had no effect on NF-B binding
to DNA (Fig. 5A), the mobilization of NF-B subunits in the
cytoplasm as measured by IB- degradation (Fig. 5B), or
NF-B subunit accumulation in the nucleus (Fig. 5C). Fur-
thermore, sPLA2-IIA in combination with TNF had no addi-
tional effect over stimulation with TNF alone in these assays.
The potent and selective sPLA2 enzyme activity inhibitor
LY311727, at a concentration (10 M) that blocks enzyme
activity and also blocks COX-2 up-regulation in FLSs (17), did
not modulate NF-B mobilization by TNF/sPLA2-IIA (Fig. 5).
In addition, sPLA2-IIA alone, again unlike TNF, did not in-
duce p38 phosphorylation (Fig. 6A), nor did it modulate TNF-
dependent phosphorylation. As with NF-B mobilization,
blockade of sPLA2-IIA with LY311727 had no effect on p38
phosphorylation in the presence of TNF/sPLA2-IIA (Fig. 6A).
Unstimulated FLSs show significant basal ERK activation that
was further stimulated by treatment with sPLA2-IIA or TNF
alone (Fig. 6B). However, sPLA2-IIA did not augment TNF-
dependent ERK phosphorylation, despite TNF being at a low
(submaximal) concentration (50 pg/ml). In contrast to its effect
of abrogating COX-2 up-regulation (18), LY311727 had no effect
on TNF/sPLA2-IIA-mediated ERK activation (Fig. 6B).
DISCUSSION
These data establish for the first time in cultured cells rele-
vant to the pathogenesis of RA that the regulation of TNF-de-
pendent PG production by exogenous sPLA2-IIA does not
depend on its enzyme function. sPLA2-IIA mutant, H48Q,
which retains only 1% of sPLA2-IIA enzyme activity, is as ef-
fective as the fully functional enzyme in up-regulating PGE2
production and in superinducing TNF-mediated COX-2 pro-
duction (Fig. 1). H48Q alone up-regulates the production of
COX-2 without increasing PGE2 production (Fig. 1B), as does
sPLA2-IIA (18). It is very unlikely that the sPLA2-IIA and
H48Q effects are mediated by low-level contaminants because
the effects we measure on PGE2 production and COX-2 up-
regulation by sPLA2-IIA are completely abrogated by
LY311727 (10 M) (18), indicating that they are intrinsic to
sPLA2-IIA. Importantly, our earlier study also showed that
the augmentation of TNF-induced PGE2 production by wild-
type sPLA2-IIA depends on the amount of sPLA2-IIA added.
For example, addition of 1 g/ml of sPLA2-IIA together with
TNF led to only 50% as much PGE2 production as did addi-
tion of 10 g/ml of sPLA2-IIA together with TNF (18). Our
observations that 4 g/ml of H48Q gives the same level of
PGE2 production as 4 g/ml of wild-type sPLA2-IIA (Fig. 1A)
and that the H48Q response is dose-dependent, shows that
the augmentation of PGE2 production is not due to the resid-
ual 1% enzymatic activity of H48Q. We have recently shown4
that complete abrogation of sPLA2-IIA enzyme activity with
the covalent active site modifier bromophenacylbromide also
did not affect PGE2 production. Although these findings may
appear to conflict with our observation that LY311727 (a po-
tent inhibitor of sPLA2-IIA catalytic activity) also blocks PGE2
production and COX-2 up-regulation (18), they argue that
LY311727 acts as a dual-function sPLA2-IIA inhibitor. Our
finding is consistent with other observations that LY311727
can inhibit other catalytic activity-independent functions of
sPLA2-IIA such as M-type receptor binding (46). Interest-
ingly, the cyclic peptide inhibitor c2, demonstrated to block
AA mobilization here, also blocks PGE2 production in FLS
(26), indicating that it is a dual-function sPLA2-IIA inhibitor
also.
Our studies provide important and unexpected insights
into the regulation of the AA metabolism in RA FLSs. First
(Fig. 7), AA mobilization in resting FLSs appears high (10–
15% over 2 h) in comparison to other resting cell lines (1–2%)
(47). Basal AA mobilization is partially suppressible by inhibi-
tors of cPLA2-, (Fig. 3C), but not by inhibitors of sPLA2-IIA
(Fig. 4A) or iPLA2- (data not shown). Analysis of the distri-
bution of tritium in conditioned medium from these cells (Ta-
ble 1) suggests that the majority of mobilized AA remains
esterified in phospholipids. The apparently high basal AA
mobilization is thus likely due to microparticle release. The
20% of tritium coeluting with AA correlates well with the pro-
portion of AA mobilization that is suppressible by cPLA2-
inhibition (Fig. 3C) suggesting that basal AA release is likely
4 L. Lee, P.-W. Lei, K. J. Bryant, E. P. Huang, S. Harrop, P. M. Curmi, A. P. Duff,
W. B. Church, and K. F. Scott, manuscript in preparation.
TABLE 1
Distribution of 3H in supernatants of FLSs as measured by thin layer
chromatography
3H in TLC fractions (% total 3H)
Sample PL (Rf< 0.07) AA (Rf> 0.81)
Other
(0.07 < Rf < 0.81)
[3H]AA controla 4.6 0.2b 86 1 9.6 0.8
No stimulus control 63 5 20 9 17 8
TNF 52 5 39 6 8 2
sPLA2-IIA 16 1c 43 17 41 16
TNF sPLA2-IIA 15 2c 60 18 25 16
a Purified [3H]AA standard. Total 3H in sample6800 dpm for each experiment.
b Data are mean S.E. of data from three separate experiments. In the case of
FLSs, data represent 3 independent FLS cultures. Total 3H in FLS samples
ranged from 1169 to 2781 dpm.
c p	 0.001 relative to “no stimulus” control (two-way analysis of variance using
data from cell culture experiments, Bonferonni’s multiple comparison test).
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FIGURE 5. sPLA2-IIA does not activate or enhance TNF activation of the NF-B pathway in RSF. A, EMSA. Single flasks of 90% confluent FLSs were stim-
ulated for 1 h in DMEM/Ham’s F-12 containing 0.1% BSA with TNF (10 pg/ml), sPLA2-IIA (5 g/ml), TNF/sPLA2-IIA or TNF/sPLA2-IIA with LY311727 (10 M).
Nuclear protein extracts were prepared and binding to a radiolabeled NF-B consensus binding sequence was determined by EMSA as described under
“Experimental Procedures.” Binding specificity to detected bands was confirmed by supershift assays with anti-p65 or anti-p50 Abs relative to an isotype-
matched control Ab in extracts of TNF-stimulated cells as indicated. B, IB degradation. Single flasks of 90% confluent FLSs (n 3) in DMEM/Ham’s F-12
containing 0.1% BSA were stimulated for 15 min with sPLA2-IIA (5 g/ml), TNF (50 pg/ml), TNF/sPLA2-IIA or TNF/sPLA2-IIA with LY311727 (10 M). Total cell
lysates were prepared. IB, IB, and -actin protein were detected by Western blot analysis. The ratio of IB to -actin protein was quantified by densi-
tometry and is normalized to the ratio measured in unstimulated cells. Data are mean S.E. (n 3). C, nuclear NF-B p65 and p50 protein in FLSs. Single
flasks of 90% confluent RSF (n 3) in DMEM/Ham’s F-12 containing 0.1% BSA were stimulated for 1 h with TNF (10 pg/ml), sPLA2-IIA (5 g/ml), TNF/sPLA2-
IIA or TNF/sPLA2-IIA with LY311727 (10 M). Nuclear protein extracts were prepared. Nuclear c-Jun, NF-B p65 and p50 protein were detected by Western
blot analysis. The ratio of nuclear NF-B p65 and p50 to c-Jun protein was quantified by densitometry and normalized to the ratio measured in unstimu-
lated cells. Data are mean S.E. (n 3 independent FLS cultures).
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cPLA2--dependent. Under resting conditions, a small
amount of PGE2 production is detectable, which is not sup-
pressible by COX-2 selective inhibitors (18), suggesting PGE2
production likely couples to COX-1 in these circumstances.
Second (Fig. 7), AA mobilization following stimulation with
TNF or BK is dependent on enhanced cPLA2- activity be-
cause pyrrophenone blocks agonist-induced AA mobilization
(Fig. 3C). Thus, TNF alone, although inefficient at rapidly mo-
bilizing calcium in most cells, activates cPLA2-, probably via
enhancing cPLA2- phosphorylation, as established in other
model cell lines (2). cPLA2- activation results in an50%
increase over basal in AA mobilization (Fig. 3C) with this in-
crease likely distributed to AA, because no change is seen in
the distribution of tritium in phospholipid relative to un-
stimulated cells (Table 1). Increased steady-state levels of
COX-2 protein (Figs. 1B and 2C) also contribute to the 8–10-
fold increase in COX-2-dependent PGE2 production (Figs. 1A
and 2B) seen on TNF stimulation.
Third (Fig. 7), increased AA mobilization by sPLA2-IIA
(Figs. 3C and 4) is mediated directly by its enzyme function
not by cPLA2-. H48Q fails to mobilize AA (Fig. 4B) and pyr-
rophenone does not block the effect (Fig. 3C). Importantly the
distribution of mobilized tritium esterified in phospholipids is
significantly lower in sPLA2-IIA-stimulated cells than that
seen in unstimulated cells, indicating that exogenous sPLA2-
IIA mobilizes AA from microparticle phospholipid pools. The
trend to increased tritium distribution into other lipid media-
tors suggests that sPLA2-IIA-derived AA may be metabolized
into eicosanoids. Because sPLA2-IIA alone does not increase
PGE2 production (Fig. 1A) and the majority of the tritium
eluted at Rf values between 0.67 and 0.81 (data not shown),
these data are consistent with the metabolites being hy-
droxyeicosatetraenoic acids, although further work is neces-
sary to confirm this. Importantly, increased AA mobilization
in FLSs requires concentrations of exogenous sPLA2-IIA
above 70 nM (1 g/ml), 7–70-fold higher than the concentra-
tions required for activity-dependent enhanced proliferation
in prostate cancer cells (37). Exogenous sPLA2-IIA is not as
potent in AA mobilization from resting cells as some other
sPLA2 forms present in RA synovial tissue, notably Group X
sPLA2 (38). However, effective sPLA2-IIA concentrations are
within the range of concentrations measured in RA synovial
fluids suggesting that sPLA2-IIA may contribute to AA mobi-
FIGURE 6. sPLA2-IIA does not activate p38MAP kinase in FLSs but acti-
vates ERK. Single flasks of 90% confluent FLSs (n 3) in DMEM/Ham’s F-12
containing 0.1% BSA were stimulated for 15 min with sPLA2-IIA (5 g/ml),
TNF (50 pg/ml), TNF/sPLA2-IIA or TNF/sPLA2-IIA with LY311727 (10 M). To-
tal cell lysates were prepared, and A, phosphorylated p38 and total p38
MAP kinase protein, or B, p-ERK and total ERK were detected by Western
blot analysis as described under “Experimental Procedures.” Representative
Western blots and the ratio of phospho- to total MAP kinase protein nor-
malized relative to unstimulated cells is shown. Data are mean S.E. (n 3
independent FLS cultures). Control phospho-MAPK/total MAPK ratios varied
between cultures from 0.281 to 0.455 for p38, 0.432 to 0.671 for ERK-1, and
0.454 to 0.831 for ERK-2 (*, p	 0.05 relative to control, Student’s paired t
test).
FIGURE 7.Model of sPLA2-IIA function in FLS AAmetabolism. Unstimu-
lated cells, AA is mobilized in microparticles esterified to phospholipids.
Low level AA release is mediated by cPLA2- and is reincorporated into
phospholipid pools by acylase(s). AA flux to PGE2 is very low and is via
COX-1. TNF-stimulated cells, TNF. cPLA2- is activated (Q) and COX-2 ex-
pression is induced (1 in circle), stimulating AA flux through the COX-2
pathway to stimulate PGE2 production. TNF sPLA2-IIA, sPLA2-IIA enzyme
activity increases AA mobilization that is not coupled to PGE2 production.
sPLA2-IIA-mediated signaling superinduces COX-2 (11 in circle) resulting
in increased cPLA2--dependent AA flux through COX-2 to PGE2. sPLA2-IIA
alone increases AA release and induces COX-2 without increasing PGE2 pro-
duction. The figure is modeled after Fitzpatrick and Soberman (51).
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lization in pathological conditions such as RA, where enzyme
concentrations are high.
FLSs appear more sensitive to AA mobilization by exoge-
nous sPLA2-IIA than other attachment-dependent cells. No
detectable AA release was observed in CHO cells (38) or HEK
293 cells (47) at sPLA2-IIA concentrations up to 1 or 10 g/
ml, respectively, even following 6 h stimulation. Thus, FLSs
have a stable metabolic “phenotype” not seen in other attach-
ment-dependent cells that allows exogenous sPLA2-IIA-medi-
ated AA mobilization. Although it is known that micropar-
ticle membranes express phosphatidylserine on their surface,
the structural characteristics of FLS membranes have not yet
been studied in detail, so whether membrane lipid asymmetry
has been stably altered in FLSs remains to be determined.
AA mobilized by sPLA2-IIA, either alone or in combination
with TNF, is not utilized for PGE2 production, despite the
induction of COX-2. In the case of sPLA2-IIA stimulation
alone, no increased PGE2 production is observed (Fig. 1A) and
in the case of costimulation with TNF, abrogation of sPLA2-
IIA enzyme activity by mutagenesis does not affect PGE2 pro-
duction (Fig. 1A) and all of the observed increase in PGE2
production is suppressible by cPLA2- inhibitors (Fig. 2, A
and B). Thus under all conditions examined, only cPLA2-
activation can account for AA flux to PGE2.
The functional coupling of cPLA2- and COX-2, also seen
in other cell lines (48), is particularly striking in FLSs: despite
effectively blocking TNF or bradykinin-mediated AA mobili-
zation, inhibition of cPLA2- in the presence of both TNF
and sPLA2-IIA has no significant effect on AA mobilization
(Fig. 3C), although effectively blocking all PGE2 production
(Fig. 2). Under these conditions, over 20% of incorporated AA
is mobilized from cells, yet only a very small proportion of
released AA contributes to PGE2 production, all of it gener-
ated by cPLA2- activity. Exogenous sPLA2-IIA is thus not
functionally coupled to the COX pathway as has been com-
monly proposed (49–51), but rather indirectly regulates PG
production pathways in these cells (Fig. 7). Our data also ar-
gue against regulation of cPLA2- activity by sPLA2-IIA as
has been found with other cell types (52), because sPLA2-IIA
alone is unable to induce PGE2 production, despite up-regu-
lating COX-2. In the presence of sPLA2-IIA alone, provision
of AA to COX-2 by cPLA2- is the rate-limiting step in PGE2
production. In contrast, in the presence of TNF, PGE2 pro-
duction is limited by the amount of COX-2. Thus the rate-
limiting step in the pathway may be either cPLA2- or COX-2
depending on the cellular context.
Fourth (Fig. 7), the contribution of sPLA2-IIA to the 10–
60-fold increased PGE2 production over basal levels seen on
costimulation with TNF can be fully explained by enzyme
activity-independent superinduction of the steady state levels
of COX-2. The H48Q mutation does not affect the ability of
sPLA2-IIA to induce COX-2 (Fig. 1B). As with NS-398 (18),
concentrations of pyrrophenone that completely suppress
PGE2 production do not affect the induction of COX-2 by
sPLA2-IIA (Fig. 2C). It follows then, that cPLA2- or sPLA2-
IIA-derived AA or its metabolites do not regulate COX-2 pro-
tein levels in sPLA2-IIA-stimulated RA FLSs. This is in con-
trast to COX-2 up-regulation by IL-15 (53) or by certain
agonists in other cell types (54, 55) whereby stimulus-induced
PGE2 further up-regulates COX-2.
Although exogenous sPLA2-IIA up-regulates COX-2 pro-
tein in some model cell lines, the effect is cell-type specific
(50), and apart from one case, nerve growth factor-stimulated
rat serosal mast cells, where up-regulation also appears inde-
pendent of enzyme activity (56), the mechanism is unknown.
We have ruled out rapid activation of NF-B or p38 MAPK by
sPLA2-IIA, two pathways known to mediate agonist-depen-
dent COX-2 up-regulation in FLSs (43, 57); sPLA2-IIA alone
activates the ERK MAPK pathway. Although modest, ERK
activation demonstrates that sPLA2-IIA regulates intracellular
signaling and suggests broader effects on RA FLS function
than the regulation of AA metabolism alone. In addition, this
finding together with our observation that sPLA2-IIA, in the
absence of cytokine stimulation, does not induce PGE2 pro-
duction (Fig. 1A) (18), indicates that sPLA2-IIA-mediated
ERK activation alone is insufficient to stimulate prostaglandin
production in these cells, despite induction of COX-2. In our
hands, MEK inhibitors PD98059 and UO126, whereas com-
pletely suppressing TNF/sPLA2-IIA-mediated PGE2 produc-
tion did not suppress COX-2 induction (data not shown), sug-
gesting that blockade of the ERK pathway alone is insufficient
to affect COX-2 induction under these conditions. In con-
trast, we have previously shown that blockade of sPLA2-IIA
function with LY311727 is sufficient to suppress both PGE2
production and COX-2 induction in the presence of TNF
(18), yet LY311727 is unable to suppress ERK phosphoryla-
tion under these conditions (Fig. 6B). It is thus likely that TNF
is sufficient to stimulate ERK and that sPLA2-IIA effects on
PGE2 production and COX-2 expression occur “downstream”
of ERK activation. However, the importance of sPLA2-IIA-
mediated ERK activation in COX-2 up-regulation remains to
be determined.
Our data predict that sPLA2-IIA induces COX-2 expression
via an indirect signaling mechanism mediated through direct
interaction with a cellular component(s). The identity of this
component(s) in RA FLSs is unknown at present, however, in
our hands, immunofluorescence studies demonstrate that
exogenous sPLA2-IIA binds to the RA FLS cell surface and is
very rapidly (within seconds) internalized demonstrating that
the enzyme does bind to FLS cellular components.4 Receptor-
mediated sPLA2 function has been best established for Group
IB sPLA2 in mice using both biochemical and genetic ap-
proaches (58, 59). Murine Group IB sPLA2 and sPLA2-IIA
both bind the murine 180-kDa M-type sPLA2 receptor with
high affinity (1–10 nM) (59). However, human sPLA2-IIA is
reported to have a binding affinity for the human M-type re-
ceptor that is too weak for sPLA2-IIA to be a physiological
ligand in human cells (60). An alternative model is that
sPLA2-IIA is internalized via binding to heparan sulfate pro-
teoglycans, particularly glypican-1 in caveolae, followed by
subsequent AA release and/or up-regulation of COX-2 (50,
61). It has been reported that sPLA2-IIA localizes to caveolin-
containing vesicles as well as the Golgi apparatus in one “nor-
mal” synovial cell line following adenoviral transfection with
the sPLA2-IIA cDNA, suggesting that this internalization
pathway may be operative in these cells (17). However, there
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is no evidence that perturbation of this pathway has any effect
on PGE2 production. Infection of FLSs with adenoviral vec-
tors alone induces both COX-2 and PGE2 production (44)
further complicating the interpretation of viral overexpres-
sion approaches.
In summary, our data show that human sPLA2-IIA, when
added with TNF to RA FLSs, results in enhanced PGE2 pro-
duction that does not require the enzyme activity of sPLA2-
IIA. This finding, coupled with recent findings that sPLA2-IIA
can participate in intracellular AA release when stably ex-
pressed at lower concentrations than those required exog-
enously (23, 47) and that some indole inhibitors are cell im-
permeable (47) and therefore incapable of blocking
intracellular effects, suggest that clinical studies with inhibi-
tors that are known to be both cell permeable and to potently
block sPLA2-IIA-dependent signaling, may show greater ben-
efit in the treatment of RA.
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